1	Community vaccination can shorten the COVID-19 isolation		
2	period: an individual-based modeling approach		
3 4	Chayanin Sararat ¹ , Jidchanok Wangkanai ¹ , Chaiwat Wilasang ¹ , Tanakorn Chantanasaro ¹ , and Charin Modchang ^{1,2,3*}		
5 6	¹ Biophysics Group, Department of Physics, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.		
7	² Centre of Excellence in Mathematics, MHESI, Bangkok 10400, Thailand.		
8 9	³ Thailand Center of Excellence in Physics, Ministry of Higher Education, Science, Research and Innovation, 328 Si Ayutthaya Road, Bangkok 10400, Thailand.		
10			
11			
12	* Corresponding author		
13	E-mail: <u>charin.mod@mahidol.edu</u>		
14			
15			
16			
17			
18			
19			
20			
21			
22			
23	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.		

Abstract 24

25 Background: Isolation of infected individuals and guarantine of their contacts are usually 26 employed to mitigate the transmission of SARS-CoV-2. While 14-day isolation of infected 27 individuals could effectively reduce the risk of subsequence transmission, it also significantly 28 impacts the patient's financial, psychological, and emotional well-being. It is, therefore, vital 29 to investigate how the isolation duration could be shortened when effective vaccines are 30 available and in what circumstances we can live with COVID-19 without isolation and 31 quarantine.

32 Methods: An individual-based modeling approach was employed to estimate the likelihood of 33 secondary infections and the likelihood of an outbreak following the isolation of an index case 34 for a range of isolation periods. Our individual-based model integrates the viral loads and 35 infectiousness profiles of vaccinated and unvaccinated infected individuals. The effects of 36 waning vaccine-induced immunity against Delta and Omicron variant transmission were also 37 investigated.

38 Results: In the baseline scenario in which all individuals are unvaccinated, and no 39 nonpharmaceutical interventions are employed, there is a chance of about 3% that an 40 unvaccinated index case will make at least one secondary infection after being isolated for 14 41 days, and a sustained chain of transmission can occur with a chance of less than 1%. We found 42 that at the outbreak risk equivalent to that of 14-day isolation in the baseline scenario, the 43 isolation duration can be shortened to 7.33 days (95% CI 6.68-7.98) if 75% of people in the 44 community are fully vaccinated during the last three months. In the best-case scenario in which 45 all individuals in the community are fully vaccinated, isolation of infected individuals may no 46 longer be necessary. However, to keep the outbreak risk low, a booster vaccination may be 47 necessary three months after full vaccination. Finally, our simulations showed that the reduced 48 vaccine effectiveness against transmission of the Omicron variant does not much affect the risk 49 of an outbreak if the vaccine effectiveness against infection is maintained at a high level via 50 booster vaccination.

Conclusions: The isolation duration of a vaccine breakthrough infector could be safely 51 52 shortened if a majority of people in the community are immune to SARS-CoV-2 infection. A 53 booster vaccination may be necessary three months after full vaccination to keep the outbreak 54 risk low.

55

Background 56

57 SARS-CoV-2 spreads rapidly throughout the world, causing over 288.23 million 58 infections and 5.48 million deaths by the end of 2021 [1]. During the early phase of 59 transmission, when vaccines were unavailable, nonpharmaceutical interventions have been 60 frontline measures to mitigate the transmission [2, 3]. Isolation of infected individuals is a 61 critical strategy widely employed to break the transmission chain. Institution-based isolation 62 of confirmed cases has been shown in a modeling study to delay the epidemic's peak and reduce 63 the epidemic's size by approximately 57% [4]. Isolation, however, will be effective only if it 64 can be promptly employed to prevent pre-symptomatic and asymptomatic transmission [5]. In 65 addition, the isolation period should also be long enough to ensure that the infected individuals 66 do not spread the disease after the isolation. However, while prolonged isolation may reduce 67 the risk of transmission more effectively, it also significantly impacts the patient's financial, 68 psychological, and emotional well-being [6-8].

69 COVID-19 vaccines were first made available in the last of 2020 [9], and they have 70 been shown to be effective at preventing infection and transmission [10-12]. Despite the fact 71 that infections can occur even after being fully vaccinated, a faster viral clearance was observed 72 in the breakthrough infections, indicating that a breakthrough infected individual may have a shorter duration of infectiousness [13, 14]. As a result, it suggests that those who have been 73 74 vaccinated may require a shorter period of isolation. It is vital to comprehend how the isolation 75 period could be reduced based on vaccine effectiveness, particularly when we desire to return 76 to normalcy and live with COVID-19 without quarantine and isolation measures.

77 In this study, we used an individual-based modeling approach to assess the likelihood of secondary infections and the likelihood of an outbreak following isolation of a vaccinated 78 79 index case for a range of isolation periods. Our individual-based model accounts for 80 transmission heterogeneity, variation in the course of infection, and the disease's infectivity 81 profiles of both vaccinated and unvaccinated infected individuals. The effects of waning 82 vaccine-induced immunity and the delay in isolating infected individuals in the community 83 were also examined.

85 Methods

86 Estimation of infectiousness profiles and vaccine efficiency against 87 transmission


88 Individuals infected with SARS-CoV-2 can become infectious prior to the onset of 89 symptoms. In the case of unvaccinated individuals, the infectiousness peaks 2.1 days before the onset of symptoms and then decreases gradually during the course of the illness [15]. 90 91 Although the viral trajectories during the proliferation stage are similar in both unvaccinated 92 and vaccinated individuals, the viral loads are cleared faster in vaccine breakthrough infections 93 than in the unvaccinated individuals [13, 14]. The disease infectiousness (F) prior to the peak 94 of both vaccinated and unvaccinated infectors was therefore assumed to follow a gamma 95 distribution, as described in [15]. After the peak period, data on C_t values collected in Singapore 96 [13] were used to determine the infectiousness profile. The infectiousness was considered to be directly proportional to the viral load (V) that exceeds a threshold of 10^6 copies, i.e., 97 $F \propto V x 10^{-6}$ [16]. C_t values were converted to viral load (V) using the procedures outlined in 98 99 [14]. Because of the faster viral clearance time, the disease transmissibility of vaccinated 100 infectors could be averted compared to unvaccinated ones. In this work, we estimated the 101 vaccine efficacy against transmission from a percentage of reduction in the area under the 102 curves of the disease infectiousness profiles of vaccinated and unvaccinated infectors.

103

104 Model structure

105 In order to examine the probability of post-isolation infections, the transmissions of the 106 COVID-19 were simulated with individuals categorized as susceptible (S), latent (L), infectious (I), recovered (R), isolated (Q), and fully vaccinated (V) according to their infection and 107 108 vaccination status. Infectious individuals are further divided into symptomatic (I_S) and 109 asymptomatic (I_A) infectious individuals, with the assumption that asymptomatic infectious 110 individuals are less infectious than symptomatic ones. Although COVID-19 vaccines cannot entirely protect people against infection, they are still beneficial in decreasing the chance of 111 112 infection. In addition, even when vaccinated individuals get infected, they will be less likely to 113 transmit the disease to other individuals. In our model, vaccine breakthrough infections are 114 distinguished from infections in susceptible individuals by subscripts V and S, as shown in

- 115 Figure 1(A). After being infected, individuals enter a latent state before becoming infectious.
- 116 Finally, infectious individuals move either to recovered or isolated compartments.



118 Figure 1: Model structure of the COVID-19 transmission. (A) Schematic of the 119 compartmental model showing progressive of the disease and transition of individuals across 120 different compartments. (B) Example of the expected number of secondary cases made by a 121 single primary case drawn from a negative binomial distribution. (C) An illustration of 122 transmission events due to the primary case (red circle). The generation time is a time duration 123 between a primary case's infection and one of its subsequent secondary cases. The incubation 124 period is a time duration from exposure to symptom onset. The inset shows the infectiousness 125 profiles of unvaccinated (UV) and vaccinated (V) infected individuals.

126

The number of secondary infections caused by a single primary case, Z, for each 127 128 infected individual is estimated from a negative binomial distribution with a mean equal to the 129 reproduction number (R_{θ}) and dispersion parameter (k) (Figure 1(B)). Because of the lower 130 infectivity of asymptomatic infectious individuals, they contribute fewer infections; the mean number of secondary cases made by an asymptomatic infectious individual was reduced by a 131 factor r. For the vaccine breakthrough infectors, the mean of the distribution is also reduced 132 due to the efficiency against transmission of vaccines (e_l) . 133

134 An example of the transmission events is illustrated in Figure 1(C). The incubation 135 period, time from exposure to symptom onset, is assumed to follow the Gamma distribution 136 with a mean of 5.8 days [15]. The time of each new infection is drawn from a random number 137 distribution that is distributed according to the infectiousness profile of the infectors. As a result 138 of the vaccine's effectiveness against infection, vaccinated individuals are less likely to become 139 infected. The effective infectious period is determined by whether or not infected individuals 140 are isolated. If infected individuals are isolated, they will be contagious until they are isolated. 141 Although transmission can be prevented during isolation, post-isolation infections are still 142 possible. The generation time between infection of a primary case and one of its subsequent 143 secondary cases is dependent on both the incubation period and the infection time. In our study, 144 the primary index case is assumed to be isolated immediately after becoming infected, whereas 145 other subsequent infected individuals in the community are isolated with a default time delay of 6.8 days. 146

147

Estimating the probability of secondary transmission and the probability of 148 a successful outbreak after isolation 149

150 The probability of secondary transmission was defined as a chance that a primary case 151 makes at least one subsequence infection after the isolation. The probability of a successful 152 outbreak was estimated from the likelihood that the chain of transmission initiated from the 153 index case after isolation continues for more than 90 days. We have checked that the threshold 154 value of 90 days can distinguish between simulations in which the disease goes extinct and 155 simulations in which the disease spreads substantially until reaching the equilibrium state. The

- 156 probabilities were estimated using three batches of simulations, each containing 1,000
- 157 realizations.
- 158

159 **Table 1: Model parameters and their default values**

Parameter	Default value	Source
Basic reproduction number (R_0)	5.08	[17]
Overdispersion parameter (k)	0.08	[18]
Incubation period distribution (Gamma distribution)	5.8 days	
- Mean	3.64	[15]
- Shape parameter		
- Scale parameter	1.59	
Probability of being symptomatic		
- Unvaccinated individuals	0.573	[19]
- Vaccinated individuals	0.431	[19]
Reduction in infectiousness of asymptomatic individual (r)	0.58	[20]
Vaccine effectiveness against infection (e_S)	0.79	[12]
Vaccine effectiveness against transmission (<i>e</i> ₁)	0.25	Estimation
Probability that symptomatic individuals will be isolated	0.8	Assumption
Probability that asymptomatic individuals will be isolated	0.1	Assumption
Time delay from infection to isolation		
- Index case	0 days	Assumption
- Infected individuals in community	6.8 days	Assumption

Results 161


Impact of vaccination on post-isolation transmission 162

We explored the probability of a primary infected individual making at least one 163 secondary infection and the probability of a successful outbreak, i.e., having a sustained chain 164 of transmission, after being released from isolation. In the baseline scenario in which the 165 166 primary case and all other individuals in the community are unvaccinated, we found that there 167 is a chance of about 3% that the unvaccinated index case will make at least one secondary 168 infection after being isolated for 14 days, and a sustained chain of transmission can occur with a chance of less than 1% (left bars in Figure 2(A)-(B)). However, if the index case has already 169 170 been vaccinated, we found that although all other individuals in the community are 171 unvaccinated, only about 10 days of isolation is equivalent to 14-day isolation of unvaccinated 172 index case (red lines and red symbols in Figure 2).

173 Vaccinating people in the community can further reduce the likelihood of secondary 174 infections and the probability of a successful outbreak. It was found that higher community 175 vaccine coverages decrease the chance of secondary transmission following the isolation of the 176 vaccinated index case more, especially when the isolation periods are short. In addition, when 177 the isolation period is longer than 12 days, there is no apparent difference between different 178 vaccination coverages. At the outbreak risk equivalent to that of 14-day isolation in the baseline 179 scenario, the isolation duration of the primary vaccinated infector can be shortened to 9.33 days (95% CI 8.68-9.98) if 50% of people in the community are vaccinated (Figure 2 (D)). When 180 181 75% of people in the community are vaccinated, the isolation period can be further shortened to 7.33 days (95% CI 6.68-7.98). Finally, we found that in the best-case scenario in which all 182 183 individuals are vaccinated, although post-isolation infections are still possible for the isolation 184 period of shorter than 6 days, the chance of sustained chain of transmission to occur is extremely rare. In this case, isolation of infected individuals may no longer be necessary. 185

186

187



190 Figure 2: Impacts of isolating a primary vaccinated infector on post-isolation 191 transmission. Probability of secondary transmission (A) and probability of a successful 192 outbreak in which a chain of transmission can be sustained (C) after a range of isolation periods 193 and vaccination levels in the community. The corresponding probabilities in the baseline 194 scenario where the index case and all other individuals in the community are unvaccinated are 195 shown as bar graphs on the left side of both subfigures. (B) and (D) show the isolation period 196 equivalent to the 14-day isolation period in the baseline scenarios, regarding the probability of secondary transmission and the probability of a successful outbreak, respectively. Error bars 197 198 indicate 95% CI.

199

- 200
- 201
- 202

Effect of waning vaccine-induced immunity 203

204 As the vaccine effectiveness against Delta variant infection decreases over time [21], we evaluated its effect on the probability of secondary infections and the probability of a 205 206 successful outbreak following isolation. We found that for a low level of immunization (<25% 207 coverage), both the post-isolation transmission probability and the successful outbreak 208 probability are not significantly affected by the waning of vaccine effectiveness (Figure 3 (A) 209 and (D)). However, for higher vaccine coverage, the effect of the decline in the vaccine 210 effectiveness is more pronounced, especially when the isolation durations are short. Note, 211 however, that although at high vaccination coverage (> 75% coverage), there is a more significant effect of immunity waning across a range of isolation periods, the probability of an 212 213 outbreak is still lower than that in the case when 25% of the population are vaccinated. With 214 the vaccine coverage of 75%, for example, after four months of vaccination, the outbreak risk climbs from 0.9% to 4.2% for 3-day isolation and increases from 1.3% to 7.7% for no isolation 215 216 (Figure 3 (E)). When all individuals in the community are vaccinated, despite a substantial 217 decrease in vaccine effectiveness after four months, the chance of a successful outbreak is still 218 lower than 4% even there is no isolation (Figure 3 (F)).

219 We also investigated how the change in vaccine effectiveness against transmission 220 would influence the likelihood of secondary infections and the probability of a successful 221 outbreak. In this part, we considered the vaccine effectiveness against transmission (e_l) ranges 222 from 0% to 40%, and the vaccine effectiveness against infection (e_{s}) of 90% and 50%, 223 corresponding to the effectiveness against infection of Delta variant after being fully vaccinated 224 with two doses of mRNA BNT162b2 vaccine for one month and four months, respectively. 225 We found that during the first four months after complete vaccination, when the vaccine 226 effectiveness against infection is high, the vaccine effectiveness against transmission had only 227 a minor effect on the transmission, especially when the isolation period is long (Figure 4).

- 228
- 229
- 230
- 231





Figure 3: The effect of reduction in vaccine effectiveness against SARS-CoV-2 infection. The time evolution of the probability of at least one secondary infection (A-C) and probability of a successful outbreak (D-F) following the release of a breakthrough infector from isolation as the vaccine effectiveness against infection wanes (black lines, right y-axis). Data of vaccine effectiveness against infection were obtained from reference [21].




247

248 Figure 4: The influence of vaccine effectiveness against SARS-CoV-2 transmission. The 249 probability of at least one secondary infection ((A) and (B)) and a successful outbreak ((C) and 250 (D)) after being released from isolation into a community with a vaccination level of 75%. The 251 vaccine effectiveness against transmission (e_l) was varied from 0% to 40%, and the vaccine 252 effectiveness against infection (e_s) was fixed at 90% (left column) and 50% (right column).

Impact of community case-isolation and other control measures 254

255 We next evaluated the impact of time delay from infection to the isolation of infected 256 individuals in the community on the spread of SARS-CoV-2. Our results indicated that the 257 outbreak would be less likely to occur if case isolation is performed with a shorter delay 258 (Figure 5). For example, under the vaccine coverage of 75%, the outbreak risk could be 259 suppressed to lower than 1% if the isolation can be performed within 3 days after infections. 260 To maintain the same level of an outbreak risk, a longer duration of the isolation is needed for 261 the isolation with longer delays. For instance, for a 5-day delay, at least 5 days of isolation may 262 be required, and for a 7-day delay, at least 7 days of isolation may be needed. When only 25% of individuals are vaccinated, isolation may be required for at least 10 days, regardless of how 263 264 quickly infected individuals are isolated.

265




267 Figure 5: Impact of time delay from infection to isolation under vaccination coverages 268 of (A) 25% and (B) 75%.

- 269
- 270
- 271

272 The effective reproduction number (R) is commonly used to measure the disease 273 transmissivity under different control measures. To consider the effects of other control 274 measures, a sensitivity analysis on the effective reproduction number has been performed. In 275 combination with other non-pharmaceutical interventions, we found that community 276 vaccination could further shorten the isolation period (Figure 6). For instance, in the absence 277 of any non-pharmaceutical interventions and the vaccine coverage is only 25%, case isolation 278 may be required for at least 12 days to reduce the outbreak risk to below 1%. However, if other 279 control measures are concurrently implemented at a level that could reduce the effective 280 reproduction number to 3.2, only one week of isolation is sufficient. Importantly, in this case, 281 isolation will be no longer necessary if the community vaccination level reaches 75%.







284 Figure 6: A sensitivity analysis on the effective reproduction number. The probability of a 285 successful outbreak under the community vaccination coverages of (A) 25% and (B) 75%.

286

287

288

289

Discussion 291

292 In this work, we evaluated the likelihood of at least one secondary infection and the 293 likelihood of an outbreak following the isolation of a vaccine breakthrough infector for a 294 specified period of time. Our modeling results indicated that vaccines play a critical role in 295 reducing the likelihood of post-isolation transmission. We discovered that the duration of 296 isolation for an infected individual who has already been vaccinated could be reduced as 297 opposed to the 14-day duration of isolation for unvaccinated individuals. Additionally, the 298 duration of isolation can be reduced further if the majority of the community members are 299 immune to the disease (Figure 2).

300 In the best-case scenario in which all individuals in the community are fully vaccinated 301 with two doses of mRNA BNT162b2 vaccine, isolation of Delta-variant breakthrough infected 302 individuals may no longer be required, at least during the first three months after being fully 303 vaccinated, if no other non-pharmaceutical interventions are implemented. After three months, 304 however, as the vaccine effectiveness against infection drops to around 60% [21], the 305 probability of post-isolation transmission increases rapidly after this time, especially in the 306 cases of short isolation periods. This result indicates that booster vaccination may be needed 307 after being fully vaccinated for three months; otherwise, more extended isolation periods or 308 other non-pharmaceutical control measures may be necessary to compensate for the increased 309 transmission risk (Figure 3).

310 With a faster viral clearance time in vaccinated individuals, vaccines have been 311 hypothesized to reduce onward transmission from infected vaccinated individuals. According 312 to our estimations, the vaccine effectiveness against transmission of 24.6% is comparable to the effectiveness against transmission with the Delta variant after getting two doses of the 313 314 Pfizer vaccine [22]. However, the emergence of the Omicron variant has raised serious concerns about its capability to evade vaccine protection. After receiving two doses of mRNA 315 316 vaccines, the vaccine effectiveness in preventing Omicron-variant transmission drops to less 317 than 5% [22]. Nevertheless, our simulations showed that the reduced vaccine effectiveness 318 against Omicron-variant transmission does not much affect the risk of secondary infection if 319 the vaccine effectiveness against infection is restored to a high level via booster vaccination 320 [23] (Figure 4). However, since at the time of writing this manuscript, the data on the waning 321 of vaccine effectiveness against Omicron-variant infections were not available, we assumed 322 that they wane at the same rate as the Delta variant.

When considering the effect of delay in isolation of infected individuals in the community, we found that a shorter delay to isolation can further shorten the isolation period, especially in the high vaccine coverage settings. In addition, we found that while an outbreak may still occur in the absence of isolation in the community with low vaccination coverage, the risk could be minimized when additional control measures such as contact tracing and quarantine of their contacts, as well as testing, are implemented (**Figures 5 and 6**).

329

330

331 Funding

The research is financially supported by the National Research Council of Thailand, the Thailand Center of Excellence in Physics (ThEP), the Centre of Excellence in Mathematics, the Center of Excellence on Medical Biotechnology (CEMB), the Science, Research and Innovation Promotion and Utilization Division, the Office of the Permanent Secretary Ministry of Higher Education, Science and Innovation, Thailand. Chayanin Sararat is supported by the Science Achievement Scholarship of Thailand (SAST).

338

339 Author contributions

340 CM conceived and designed the study. CS, JW, CW, and TC conducted the study. CS and CM341 analysed the results. CS and CM wrote the manuscript.

- 342
- 343
- 344
- 345
- 346
- 347

348 **References**

- Hannah Ritchie, E.M., Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban
 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser,
 Coronavirus Pandemic (COVID-19). Our World in Data, 2020.
- Wilasang, C., et al., *Reduction in effective reproduction number of COVID-19 is higher in countries employing active case detection with prompt isolation*. Journal of travel
 medicine, 2020. 27(5): p. taaa095.
- 355 3. Wilasang, C., et al., *Reconstruction of the transmission dynamics of the first COVID-*356 19 epidemic wave in Thailand. Scientific Reports, 2022. 12(1): p. 2002.
- 357 4. Dickens, B.L., et al., *Institutional, not home-based, isolation could contain the COVID-*358 *19 outbreak.* The Lancet, 2020. **395**(10236): p. 1541-1542.
- Moghadas, S.M., et al., *The implications of silent transmission for the control of COVID-19 outbreaks*. Proceedings of the National Academy of Sciences, 2020.
 117(30): p. 17513-17515.
- 362 6. Pietrabissa, G. and S.G. Simpson, *Psychological Consequences of Social Isolation* 363 *During COVID-19 Outbreak*. Frontiers in Psychology, 2020. 11(2201).
- Jain, A., et al., *Impact on mental health by "Living in Isolation and Quarantine" during COVID-19 pandemic*. Journal of family medicine and primary care, 2020. 9(10): p.
 5415-5418.
- 8. Hossain, M.M., A. Sultana, and N. Purohit, *Mental health outcomes of quarantine and isolation for infection prevention: a systematic umbrella review of the global evidence.*Epidemiology and health, 2020. 42: p. e2020038-e2020038.
- Baraniuk, C., *Covid-19: How the UK vaccine rollout delivered success, so far.* bmj,
 2021. 372.
- 372 10. Lopez Bernal, J., et al., *Effectiveness of Covid-19 vaccines against the B. 1.617. 2*373 (*Delta*) variant. N Engl J Med, 2021: p. 585-594.

- 374 11. Harris, R.J., et al., Effect of Vaccination on Household Transmission of SARS-CoV-2 in 375 England. New England Journal of Medicine, 2021. 385(8): p. 759-760. 376 12. Sheikh, A., et al., SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital 377 admission, and vaccine effectiveness. The Lancet, 2021. **397**(10293): p. 2461-2462. 378 13. Chia, P.Y., et al., Virological and serological kinetics of SARS-CoV-2 Delta variant 379 vaccine-breakthrough infections: a multi-center cohort study. medRxiv, 2021: p. 380 2021.07.28.21261295. 381 14. Kissler, S.M., et al., Viral dynamics of SARS-CoV-2 variants in vaccinated and 382 unvaccinated individuals. medRxiv, 2021: p. 2021.02.16.21251535. 383 Kang, M., et al., Transmission dynamics and epidemiological characteristics of Delta 15. 384 variant infections in China. medRxiv, 2021: p. 2021.08.12.21261991. 385 16. Larremore, D.B., et al., Test sensitivity is secondary to frequency and turnaround time 386 for COVID-19 screening. Science advances, 2021. 7(1): p. eabd5393. 387 17. Liu, Y. and J. Rocklöv, The reproductive number of the Delta variant of SARS-CoV-2 388 is far higher compared to the ancestral SARS-CoV-2 virus. Journal of Travel Medicine, 389 2021. 28(7). 390 18. Endo, A., et al., Estimating the overdispersion in COVID-19 transmission using 391 outbreak sizes outside China [version 3; peer review: 2 approved]. Wellcome Open 392 Research, 2020. 5(67). 393 19. Tang, L., et al., Asymptomatic and Symptomatic SARS-CoV-2 Infections After 394 BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA, 2021. 325(24): p. 395 2500-2502. 396 20. Byambasuren, O., et al., Estimating the extent of asymptomatic COVID-19 and its 397 potential for community transmission: systematic review and meta-analysis. Official 398 Journal of the Association of Medical Microbiology and Infectious Disease Canada,
- 399 2020. **5**(4): p. 223-234.

- 400 21. Tartof, S.Y., et al., *Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6*401 *months in a large integrated health system in the USA: a retrospective cohort study.*402 The Lancet, 2021. **398**(10309): p. 1407-1416.
- 403 22. Gardner, B.J. and A.M. Kilpatrick, *Estimates of reduced vaccine effectiveness against*
- 404 hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-
- 405 *2 variant, Omicron (B.1.1.529), using neutralizing antibody titers.* medRxiv, 2021: p.
- 406 2021.12.10.21267594.
- 407 23. Andrews, N., et al., *Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1.*408 529) variant of concern. MedRxiv, 2021.